Tevimbra

BeiGene has a total of three marketed proprietary products.

FAST NEWS: Beigene stock falls after Novartis terminates partnership

The latest: Cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) announced Tuesday that Novartis (NOVN.SWX) will relinquish its rights to co-develop, produce and commercialize BeiGene’s esophagus cancer drug tislelizumab. Looking up: Novartis will provide…
BGNE.US 6160.HK

Recent Articles

RELATED ARTICLES

  1. The innovative drug maker’s product revenue rose 82% to $747 million in the first quarter, with its star drug on pace to possibly net $2 billion for the year.
    BeiGene’s aggressive expansion brings revenue jolt
    BGNE.US 6160.HK 688235.SHG
  2. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  3. Akeso marks profit milestone with swift rights issue
    9926.HK
  4. Clinical trials come up short again for Alphamab Oncology
    9966.HK
  5. Hutchmed scores U.S. success with cancer drug, but profits still dip
    HCM.US 0013.HK
  6. Junshi narrows its losses but delivers no cure for share price woes
    1877.HK 688180.SHG
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva